Whilst prior treatments may possibly weigh heavily in producing sub-optimal responses, the use of immune checkpoint inhibitors in the neoadjuvant setting have yielded encouraging results in hormone receptor-positive/HER2-negative breast cancers [19]. This evidence concerns the gene NR4A1 and breast carcinoma.